5 research outputs found
7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimer’s Disease Treatment
Alzheimer’s disease (AD) is a debilitating progressive neurodegenerative disorder that ultimately leads to the patient’s death. Despite the fact that novel pharmacological approaches endeavoring to block the neurodegenerative process are still emerging, none of them have reached use in clinical practice yet. Thus, palliative treatment represented by acetylcholinesterase inhibitors (AChEIs) and memantine are still the only therapeutics used. Following the multi-target directed ligands (MTDLs) strategy, herein we describe the synthesis, biological evaluation and docking studies for novel 7-methoxytacrine-p-anisidine hybrids designed to purposely target both cholinesterases and the amyloid cascade. Indeed, the novel derivatives proved to be effective non-specific cholinesterase inhibitors showing non-competitive AChE inhibition patterns. This compounds’ behavior was confirmed in the subsequent molecular modeling studies
In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers
A combination of biochemical, biophysical and biological techniques was used to study calf thymus DNA interaction with newly synthesized 7-MEOTA-tacrine thiourea 12–17 and urea heterodimers 18–22, and to measure interference with type I and II topoisomerases. Their biological profile was also inspected in vitro on the HL-60 cell line using different flow cytometric techniques (cell cycle distribution, detection of mitochondrial membrane potential dissipation, and analysis of metabolic activity/viability). The compounds exhibited a profound inhibitory effect on topoisomerase activity (e.g. compound 22 inhibited type I topoisomerase at 1 µM concentration). The treatment of HL-60 cells with the studied compounds showed inhibition of cell growth especially with hybrids containing thiourea (14–17) and urea moieties (21 and 22). Moreover, treatment of human dermal fibroblasts with the studied compounds did not indicate significant cytotoxicity. The observed results suggest beneficial selectivity of the heterodimers as potential drugs to target cancer cells
Tacrine–Trolox Hybrids: A Novel Class of Centrally Active, Nonhepatotoxic Multi-Target-Directed Ligands Exerting Anticholinesterase and Antioxidant Activities with Low In Vivo Toxicity
Coupling
of two distinct pharmacophores, tacrine and trolox, endowed
with different biological properties, afforded 21 hybrid compounds
as novel multifunctional candidates against Alzheimer’s disease.
Several of them showed improved inhibitory properties toward acetylcholinesterase
(AChE) in relation to tacrine. These hybrids also scavenged free radicals.
Molecular modeling studies in tandem with kinetic analysis exhibited
that these hybrids target both catalytic active site as well as peripheral
anionic site of AChE. In addition, incorporation of the moiety bearing
antioxidant abilities displayed negligible toxicity on human hepatic
cells. This striking effect was explained by formation of nontoxic
metabolites after 1 h incubation in human liver microsomes system.
Finally, tacrine–trolox hybrids exhibited low in vivo toxicity
after im administration in rats and potential to penetrate across
blood–brain barrier. All of these outstanding in vitro results
in combination with promising in vivo outcomes highlighted derivative <b>7u</b> as the lead structure worthy of further investigation